OUTLOOK THERAPEUTICS INC (OTLK) - Total Assets
Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) holds total assets worth $18.58 Trillion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
OUTLOOK THERAPEUTICS INC - Total Assets Trend (2014–2025)
This chart illustrates how OUTLOOK THERAPEUTICS INC's total assets have evolved over time, based on quarterly financial data. Also see OUTLOOK THERAPEUTICS INC (OTLK) total market value for the company's overall valuation and market capitalisation.
OUTLOOK THERAPEUTICS INC - Asset Composition Analysis
Current Asset Composition (September 2025)
OUTLOOK THERAPEUTICS INC's total assets of $18.58 Trillion consist of 93.6% current assets and 6.4% non-current assets. Review OUTLOOK THERAPEUTICS INC (OTLK) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.5% |
| Accounts Receivable | $1.49 Million | 0.0% |
| Inventory | $3.34 Trillion | 18.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how OUTLOOK THERAPEUTICS INC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of OUTLOOK THERAPEUTICS INC for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OUTLOOK THERAPEUTICS INC's current assets represent 93.6% of total assets in 2025, an increase from 43.3% in 2014.
- Cash Position: Cash and equivalents constituted 43.5% of total assets in 2025, up from 25.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 18.0% of total assets.
OUTLOOK THERAPEUTICS INC Competitors by Total Assets
Key competitors of OUTLOOK THERAPEUTICS INC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
OUTLOOK THERAPEUTICS INC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.38 | 0.64 | 0.91 |
| Quick Ratio | 0.38 | 0.64 | 0.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-28.43 Trillion | $-15.14 Million | $-1.09 Million |
OUTLOOK THERAPEUTICS INC - Advanced Valuation Insights
This section examines the relationship between OUTLOOK THERAPEUTICS INC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.19 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 64476476.7% |
| Total Assets | $18.58 Trillion |
| Market Capitalization | $36.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values OUTLOOK THERAPEUTICS INC's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: OUTLOOK THERAPEUTICS INC's assets grew by 64476476.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for OUTLOOK THERAPEUTICS INC (2014–2025)
The table below shows the annual total assets of OUTLOOK THERAPEUTICS INC from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $18.58 Trillion | +64476476.71% |
| 2024-09-30 | $28.82 Million | -10.77% |
| 2023-09-30 | $32.30 Million | +13.23% |
| 2022-09-30 | $28.53 Million | +25.06% |
| 2021-09-30 | $22.81 Million | +15.60% |
| 2020-09-30 | $19.73 Million | +15.16% |
| 2019-09-30 | $17.13 Million | -23.10% |
| 2018-09-30 | $22.28 Million | +7.47% |
| 2017-09-30 | $20.73 Million | -12.54% |
| 2016-09-30 | $23.71 Million | +104.30% |
| 2015-09-30 | $11.60 Million | -66.85% |
| 2014-09-30 | $35.01 Million | -- |
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more